Suppr超能文献

壳聚糖及其衍生物在基于纳米载体的肺部药物递送系统中的应用。

Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.

作者信息

Dua Kamal, Bebawy Mary, Awasthi Rajendra, Tekade Rakesh K, Tekade Muktika, Gupta Gaurav, De Jesus Andreoli Pinto Terezinha, Hansbro Philip M

机构信息

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo NSW 2007, Australia.

NKBR College of Pharmacy & Research Centre, Meerut, 245 206, Uttar Pradesh, India.

出版信息

Pharm Nanotechnol. 2017;5(4):243-249. doi: 10.2174/2211738505666170808095258.

Abstract

BACKGROUND

The respiratory tract as a non-invasive route of drug administration is gaining increasing attention in the present time on achieving both local and the systemic therapeutic effects. Success in achieving pulmonary delivery, requires overcoming barriers including mucociliary clearance and uptake by macrophages. An effective drug delivery system delivers the therapeutically active moieties at the right time and rate to target sites. A major limitation associated with most of the currently available conventional and controlled release drug delivery devices is that not all the drug candidates are well absorbed uniformly locally or systemically.

METHODS

We searched and reviewed the literature focusing on chitosan and chitosan derivative based nanocarrier systems used in pulmonary drug delivery. We focused on the applications of chitosan in the development of nanoparticles for this purpose.

RESULTS

Chitosan, a natural linear bio-polyaminosaccharide is central in the development of novel drug delivery systems (NDDS) including nanoparticles for use in the treatment of various respiratory diseases. It achieves this through its unique properties of biodegradability, biocompatibility, mucoadhesivity and its ability to enhance macromolecule permeation across membranes. It also achieves sustained and targeted effects, primary requirements for an effective pulmonary drug delivery system. This review highlights the applications and importance of chitosan with special emphasis on nanotechnology, employed in the management of respiratory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), lung cancer and pulmonary fibrosis.

CONCLUSION

This review will be of interest to both the biological and formulation scientists as it provides a summary on the utility of chitosan in pulmonary drug delivery systems. At present, there are no patented chitosan based controlled release products available for pulmonary drug delivery and so this area has enormous potential in the field of respiratory science.

摘要

背景

呼吸道作为一种非侵入性给药途径,在实现局部和全身治疗效果方面正日益受到关注。实现肺部给药的成功,需要克服包括黏液纤毛清除和巨噬细胞摄取在内的障碍。有效的药物递送系统能在正确的时间和速率将治疗活性部分递送至靶部位。与目前大多数现有的传统和控释药物递送装置相关的一个主要限制是,并非所有候选药物都能在局部或全身被均匀良好地吸收。

方法

我们检索并综述了聚焦于用于肺部药物递送的基于壳聚糖和壳聚糖衍生物的纳米载体系统的文献。我们着重关注壳聚糖在此目的纳米颗粒开发中的应用。

结果

壳聚糖是一种天然线性生物聚氨基糖,在新型药物递送系统(包括用于治疗各种呼吸道疾病的纳米颗粒)的开发中起着核心作用。它通过其独特的生物可降解性、生物相容性、黏膜黏附性以及增强大分子跨膜渗透的能力来实现这一点。它还实现了持续和靶向作用,这是有效肺部药物递送系统的主要要求。本综述强调了壳聚糖的应用和重要性,特别着重于纳米技术,其应用于哮喘、慢性阻塞性肺疾病(COPD)、肺癌和肺纤维化等呼吸道疾病的管理。

结论

本综述对于生物科学家和制剂科学家都将具有参考价值,因为它总结了壳聚糖在肺部药物递送系统中的效用。目前,尚无基于壳聚糖的用于肺部药物递送的专利控释产品,因此该领域在呼吸科学领域具有巨大潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验